KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Hypertension Mortality Rose Significantly from 1999 to 2019 September 3, 2025With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.
- Achieving PBM Reform Through Public Engagement, Advocacy September 3, 2025Regardless of which stakeholders are involved, a collective, team effort is necessary to achieve state- and federal-level PBM reform.
- Transitions of Care and Unmet Needs in Hyperkalemia Management September 3, 2025An expert discusses the critical risks of care transitions for hyperkalemia patients, emphasizing the pharmacist’s essential role in ensuring medication safety, effective communication, and continuity of care, while highlighting the potential of predictive tools and novel therapies to improve early detection and long-term management.
- CVS, Walgreens Will Limit COVID-19 Vaccine Offerings in 16 States September 2, 2025CVS will not offer COVID-19 vaccines in Massachusetts, Nevada, and New Mexico.
- Wegovy Outperforms Tirzepatide in Reducing Major Adverse Cardiovascular Events September 2, 2025A real-world study found that semaglutide significantly reduced the risk of major cardiovascular events compared to tirzepatide.
- Community Health Programs Improved Outcomes Among Black Patients September 2, 2025Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.
- FDA Approves Biosimilars for Prolia, Xgeva September 2, 2025The FDA approves denosumab-nxxp (Bildyos and Bilprevda), enhancing access to vital bone health treatments for osteoporosis and cancer-related conditions.
- Prescription-to-OTC Switch of Triptans Showed Positive Public Health Impact September 2, 2025Detailing the public health impact of an Rx-to-OTC switch, researchers explored the reclassification of triptan medications in Germany.
- Q&A: Equity in Pharmacy Means Meeting Patients Where They Are September 2, 2025Pharmacists advance equity by personalizing care and addressing health literacy to meet patients where they are.
- FDA Approves Lecanemab Subcutaneous Formulation as Maintenance Dose for Alzheimer Disease September 2, 2025FDA approves Leqembi's subcutaneous formulation, enhancing accessibility for Alzheimer's treatment and paving the way for future combination therapies.
Pharmacy Times articles
- Potential for Precision: Exploring Targeted Therapies in mCRC Care September 4, 2025Panelists discuss how the importance of having pharmacists embedded in oncology clinics has transformed metastatic colorectal cancer care by enabling real-time decision-making and dose adjustments, while highlighting that these are exciting times with multiple new oral treatment options that patients often prefer over infusions, though managing adherence and side effects remains challenging, and emphasizing that […]
- A Pharmacist’s View of Emerging CML Treatment September 4, 2025A panelist discusses how emerging chronic myeloid leukemia treatment advancements, including the addition of asciminib as a frontline tyrosine kinase inhibitor (TKI) option and ongoing research into dual TKI therapy and optimal dosing strategies, are expanding therapeutic choices while pharmacists play a key role in educating patients and providers about evolving treatment algorithms, evaluating new […]
- API-CAT Findings Support Existing NCCN Cancer-Associated VTE Guidance September 3, 2025Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s pre-existing guidance in intermediate to high-risk cancer patients.
- Fitness, Lean Mass Linked to Reduced Anxiety and Depression in Children September 3, 2025Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.
- Women Face 45% Higher Mortality Risk From Beta-Blockers After Heart Attack September 3, 2025New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.
- Depot Medroxyprogesterone Acetate Linked to Higher Risk of Meningioma in Women September 3, 2025Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.
- Dual Inhibition of KAT6A/B and Menin: A Promising Strategy for ER+ Breast Cancer September 3, 2025By targeting 2 chromatin complexes that jointly sustain ER‑driven transcription, this combination achieves superior suppression of tumor growth and gene expression.
- Empowering Pharmacists in the Management of Patients With Urothelial Cancer September 3, 2025Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
- CMS Mailing Restrictions and Their Impact on Oncology Care Delivery September 3, 2025David Eagle, MD, Chair of Legislative Affairs and Patient Advocacy, explains how CMS’s ban on community oncology practices mailing medications creates inequities with PBMs and adds burdens for vulnerable cancer patients.
- Regardless of Kidney Function, Abelacimab Consistently Reduced Bleeding Risk in Patients With AF September 3, 2025Compared with rivaroxaban, abelacimab significantly lowered bleeding risk in patients (AF) regardless of kidney function.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com